NNC0519-0130

Peptide

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

Also in development:Obesity · Phase 2Chronic Kidney Disease · Phase 2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Chronic Kidney Disease
Obesity
Type 2 Diabetes
NCT06326047 · Novo Nordisk A/S
2024-03-18 – 2025-10-13 · Diabetes Mellitus, Type 2
What this study did
Phase 1 (8)
Obesity
NCT06718998 · Novo Nordisk A/S
2024-11-20 – 2026-01-12 · Obesity
What this study did
Type 2 Diabetes
NCT07004322 · Novo Nordisk A/S
2025-05-26 – 2026-01-28 · Diabetes Mellitus, Type 2, Obesity
What this study did
NCT06567041 · Novo Nordisk A/S
2024-08-07 – 2025-12-10 · Diabetes Mellitus, Type 2, Obesity
What this study did
NCT06513104 · Novo Nordisk A/S
2024-07-18 – 2025-09-30 · Diabetes Mellitus, Type 2
What this study did
NCT06370819 · Novo Nordisk A/S
2024-04-15 – 2024-11-27 · Diabetes Mellitus, Type 2
What this study did
NCT05870670 · Novo Nordisk A/S
2023-05-15 – 2023-10-16 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, 10 of them ahead of this one.

This drug's own stage for Chronic Kidney Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
NNC0519-0130: this drugPhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Reliable signal
NCT03436693: Incidence of 30% eGFR decline at week 104: 18.2% canagliflozin vs 29.5% placebo; intergroup difference (placebo-canagliflozin) 11.3% (95% CI 1.2-21.5, P=0.029)
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Reliable signal
NCT03036150: Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001
Difelikefalin (Korsuva)ApprovedPeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT03636269: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 54% (95% CI 43.9 to 63.9) vs Placebo 42.2% (95% CI 32.5 to 52.5)
NCT03422653: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12 (Week 12): CR845 0.5mcg/kg 51% (95% CI 42.9 to 58.9) vs Placebo 27.6% (95% CI 20.2 to 36.6)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT03594110: Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met.
NCT05373680: Adjusted mean difference in eGFR decline vs standard-of-care control: metformin +8.91 ± 1.92 (p<0.001); empagliflozin +5.1 ± 1.89 (p=0.03) — both halted CKD progression vs control.
Etelcalcetide (Parsabiv)ApprovedPeptideCalcium-sensing receptor (CaSR), allosteric agonist on parathyroid chief cellsPartial signal
NCT01785849: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 74% vs Placebo 8.3%
NCT01788046: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).): Etelcalcetide 75.3% vs Placebo 9.6%
Extended-Release Calcifediol (Rayaldee)ApprovedSmall moleculeVitamin D receptor (VDR), via conversion to calcitriolPartial signal
NCT01704079: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline (Approximately 6 months): CTAP101 30 μg Capsules 49/144 (34.0%) vs Sugar Pill to CTAP101 30 μg 5/72 (6.9%)
NCT01651000: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values (Approximately 6 months): CTAP101 30 μg Capsules 46/141 (32.6%) vs Sugar Pill to CTAP101 30 μg Capsule 6/72 (8.3%)
Ferric Carboxymaltose (Injectafer / Ferinject)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT00317239: Number of Subjects Achieving an Increase in Hemoglobin ≥1g/dL (anytime during the study): Ferric Carboxymaltose (FCM) 87/144 vs Ferrous Sulfate Tablets 35/101
Ferric Derisomaltose (Monoferric / Monofer)ApprovedIron Complex (iv)Iron repletionPartial signal
NCT02940860: Change in Hemoglobin (Hb) From Baseline to Week 8 (Baseline to week 8): Iron Isomaltoside/Ferric Derisomaltose 1.22 g/dL (95% CI 1.14 to 1.31) vs Iron Sucrose 1.14 g/dL (95% CI 1.03 to 1.26)
NCT01102413: Change in Hemoglobin (Hb) Concentration From Baseline to Week 4. (Baseline, 4 weeks): Monofer 0.57 g/dL (range -3.1 to 4) vs Iron Sulphate 0.35 g/dL (range -3.7 to 3.9)
Ferric Pyrophosphate Citrate (Triferic)
ApprovedUS marketing discontinued
Small moleculeIron-replacement therapy delivered via dialysateWeak signalNo reviewed efficacy summary in this indication
Ferumoxytol (Feraheme)ApprovedNanoparticleIV iron replacement therapyPartial signal
NCT00255424: Primary endpoint (hemoglobin change at day 35): ferumoxytol +0.82 ± 1.24 g/dl vs oral iron +0.16 ± 1.02 g/dl, P<0.0001, in favor of ferumoxytol. CT.gov's own citation list ties this Spinowitz 2008 publication specifically to NCT00255424 (not its twin trial NCT00255437).
Finerenone (Kerendia)ApprovedSmall moleculeMineralocorticoid receptorReliable signal
NCT05047263: Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001)
NCT02540993: The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death (From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months): Finerenone 504/2833 vs Placebo 600/2841
Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX)ApprovedSmall moleculeNKCC2not yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
Sucroferric Oxyhydroxide (Velphoro)ApprovedSmall moleculeDietary phosphatePartial signal
NCT03644264: Change in serum phosphorus from baseline to week 12: -0.71 (0.60) mmol/L with sucroferric oxyhydroxide vs -0.63 (0.52) mmol/L with sevelamer; difference in least squares means 0.08 mmol/L (95% CI -0.02, 0.18), meeting the pre-specified non-inferiority margin of -0.34 mmol/L
NCT01464190: Change From Baseline and Levels at Each Time Point for Serum Phosphorus (Every 4 weeks from baseline to Week 28): PA21 — Change from Baseline to Week 4 (n = 346, 236): -0.2 mg/dL (Standard Deviation 1.33); Change from Baseline to Week 8 (n = 325, 238): -0.2 mg/dL (Standard Deviation 1.38); Change from Baseline to Week 12 (n = 322, 242): 0 mg/dL (Standard Deviation 1.43); Change from Baseline to Week 16 (n = 313, 228): 0 mg/dL (Standard Deviation 1.57); Change from Baseline to Week 20 (n = 300, 221): 0 mg/dL (Standard Deviation 1.46); Change from Baseline to Week 24 (n = 286, 208): 0.1 mg/dL (Standard Deviation 1.53); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.52); Change from Baseline to Endpoint (n = 384, 260): 0.1 mg/dL (Standard Deviation 1.62) vs Sevelamer Carbonate — Change from Baseline to Week 4 (n = 346, 236): -0.1 mg/dL (Standard Deviation 1.47); Change from Baseline to Week 8 (n = 325, 238): 0.1 mg/dL (Standard Deviation 1.56); Change from Baseline to Week 12 (n = 322, 242): 0.2 mg/dL (Standard Deviation 1.55); Change from Baseline to Week 16 (n = 313, 228): 0.2 mg/dL (Standard Deviation 1.75); Change from Baseline to Week 20 (n = 300, 221): 0.1 mg/dL (Standard Deviation 1.44); Change from Baseline to Week 24 (n = 286, 208): 0.2 mg/dL (Standard Deviation 1.78); Chnage from Baseline to Week 28 (n = 287, 210): 0.2 mg/dL (Standard Deviation 1.76); Change from Baseline to Endpoint (n = 384, 260): 0.3 mg/dL (Standard Deviation 1.79)
Taurolidine / Heparin (Defencath / Neutrolin)ApprovedSmall moleculeAntimicrobial/antithrombotic catheter lock solutionReliable signal
NCT02651428: Presence of a CAC-Adjudicated Catheter-Related Bloodstream Infection (CRBSI) in Subjects Receiving Hemodialysis for the Treatment of End Stage Renal Disease (ESRD): Final Analysis (The event time was the number of days from randomization until the occurrence of a CAC-Adjudicated CRBSI or until the subject was censored. The mean participant duration of exposure to study drug was 174 days (range 4-884 days).): Neutrolin Arm 9/397 vs Heparin Arm 32/398
Tenapanor (Xphozah)ApprovedSmall moleculeNHE3 (sodium/hydrogen exchanger isoform 3)Partial signal
NCT03427125: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population (12 weeks (randomized withdrawal period)): Tenapanor 10 mg, 20 mg, 30 mg BID 0.43 mg/dL (Standard Deviation 0.199) | Placebo 1.8 mg/dL (Standard Deviation 0.196)
NCT02675998: Primary 4-week randomized-withdrawal serum phosphate change: pooled tenapanor 1.4 mg/dL vs placebo 0.6 mg/dL (p=0.01).
Vadadustat (Vafseo)ApprovedSmall moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT02680574: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 0.41 Grams per deciliter (g/dL) (Standard Error 0.036) vs Darbepoetin Alfa 0.42 Grams per deciliter (g/dL) (Standard Error 0.037)
NCT02648347: Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36) (Baseline; Weeks 24 to 36): Vadadustat 1.43 g/dL (Standard Error 0.046) vs Darbepoetin Alfa 1.38 g/dL (Standard Error 0.047)
AND017Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signalNo reviewed efficacy summary in this indication
Anrikefon (HSK21542)Phase 3PeptideKappa-opioid receptor (agonist, peripherally restricted)Reliable signal
NCT05135390: Proportion with ≥4-point WI-NRS improvement at week 12: anrikefon 37% vs placebo 15% (P<0.001)
AP301 (fiber-Iron Phosphate Binder)Phase 3Small moleculeIron-based intestinal phosphate binderPartial signal
NCT07030595: Primary 1, serum phosphate change baseline to week 12, AP301 vs sevelamer carbonate (non-inferiority, margin 0.19 mmol/L): LSM difference -0.02 mmol/L (95% CI -0.10 to 0.06), upper bound below margin, met. Primary 2, serum phosphate change week 24 to week 27, AP301 maintenance dose vs low dose: LSM difference -0.58 mmol/L (95% CI -0.69 to -0.47; P<0.001), equivalent to -1.8 mg/dL, met.
ApecotrepPhase 3Small moleculeTRPC6 (transient receptor potential cation channel subfamily C member 6)Partial signal
NCT05213624: Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 (At baseline and Week 12.): BI 764198 20 mg 48.9 Predicted percentage of patients (95% CI 29.2 to 68.6) | BI 764198 40 mg 16 Predicted percentage of patients (95% CI -1.5 to 33.5) | BI 764198 80 mg 38.5 Predicted percentage of patients (95% CI 12.2 to 64.8) vs Placebo 11.4 Predicted percentage of patients (95% CI -2.3 to 25.2)
NCT04176536: Single 40mg dose, matched-pair renal-impairment vs normal-renal-function design (NCT04176536): AUC increased 48% (moderate) / 78% (severe) renal impairment vs healthy controls; Cmax increased 14% / 12%; terminal half-life 12.7-17.4h independent of dose and renal function.
AST-120 (Kremezin)Phase 3Small moleculeOral spherical carbon adsorbentPartial signal
NCT00500682: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 1.03 (95% CI 0.84 to 1.27), P=0.78; events AST-120 178/500 vs placebo 177/502. missed
NCT00501046: Primary endpoint, time to composite of dialysis initiation, kidney transplantation or serum creatinine doubling: hazard ratio 0.91 (95% CI 0.74 to 1.12), P=0.37; events AST-120 172/500 vs placebo 183/497. missed
BalcinrenonePhase 3Small moleculeMineralocorticoid receptorPartial signal
NCT04595370: Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) missed
Baxdrostat (Baxfendy)Phase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
BHV-1400Phase 3Biologic (subtype unspecified)Gd-IgA1 (galactose-deficient IgA1)not yet gradedNo reviewed efficacy summary in this indication
Bixalomer (Kiklin)Phase 3Small moleculePhosphate binderWeak signal
NCT01742585: Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001.
NCT01742611: Mean serum phosphorus: 5.15 mg/dL at baseline, decreasing to 4.67 mg/dL at Week 12, reaching 4.58 mg/dL at Week 48 of open-label bixalomer treatment
Colestilan (Cholebine / BindRen)Phase 3Small moleculePhosphate binderPartial signal
NCT00542815: Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results).
NCT00416520: Serum phosphorus at week 16 (end of the 4-week placebo-controlled withdrawal): 0.43 mmol/L (1.32 mg/dL) lower with colestilan than with placebo (P<0.001) (Locatelli et al., Nephrol Dial Transplant 2014).
Desidustat (Oxemia)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT04215120: Change in hemoglobin baseline to week 16-24: desidustat +0.95 g/dL vs epoetin alfa +0.80 g/dL (difference 0.14 g/dL, 95% CI -0.13 to 0.42), met prespecified noninferiority margin; hemoglobin responders 59.22% desidustat vs 48.37% epoetin alfa (p=0.0382)
NCT04012957: Change in hemoglobin baseline to week 16-24: desidustat +1.95 g/dL vs darbepoetin +1.83 g/dL (difference 0.11 g/dL, 95% CI -0.12 to 0.34), met prespecified noninferiority margin of -0.75 g/dL; hemoglobin responders 77.78% desidustat vs 68.48% darbepoetin (p=0.0181)
ElecoglipronPhase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EnarodustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT06016036: Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001
NCT04027517: 평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL)
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2not yet gradedNo reviewed efficacy summary in this indication
HRS-1780Phase 3Small moleculeMineralocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Imlifidase (Idefirix)Phase 3Protein / enzyme therapeuticImmunoglobulin G (IgG), all four human subclassesWeak signal
NCT02790437: Crossmatch conversion (positive to negative) within 24 hours of IdeS dosing: 17 of 19 patients converted; 2 of 19 did not.
Iptacopan (Fabhalta)Phase 3Small moleculeComplement Factor BPartial signal
NCT04578834: Final analysis: annualized total eGFR slope over 24 months, iptacopan -3.10 vs placebo -6.12 mL/min/1.73 m2 per year; difference 3.02 (95% CI 2.02 to 4.01), adjusted P<0.001. Interim (month 9): 24-hour UPCR 38.3% lower with iptacopan (95% CI 26.0 to 48.6), P<0.001. Both primaries met.
NCT03373461: MCP-Mod Estimates of the Ratio to Baseline of Urine Protein to Creatinine Ratio (UPCR) (g/Mol) - Parts 1 and 2 at Day 90 (Baseline and Day 90): LNP023 10 mg BID 0.85 Ratio to baseline (95% CI 0.77-0.93) vs LNP023 50 mg BID 0.80 Ratio to baseline (95% CI 0.73-0.87) vs LNP023 100 mg BID - Part 2 0.76 Ratio to baseline (95% CI 0.70-0.81) vs LNP023 200 mg BID 0.69 Ratio to baseline (95% CI 0.61-0.77) vs Placebo 0.88 Ratio to baseline (95% CI 0.80-1.00); p=0.038 (LNP023 10 mg BID vs LNP023 50 mg BID vs LNP023 100 mg BID - Part 2 vs LNP023 200 mg BID vs Placebo)
JR-131Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT02912494: Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL
Loncipoetin Alfa (NuPIAO)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signal
NCT05211167: Reached its pre-set primary endpoint (3SBio 2023 annual report; trial completed January 2024); no figures were given.
MezagitamabPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
MolidustatPhase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Partial signal
NCT03543657: Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established
NCT03350347: Mean Hb during the week 30-36 evaluation period: 11.67 g/dL molidustat vs 11.53 g/dL darbepoetin; LS mean difference 0.13 g/dL (95% CI -0.15 to 0.40), inside the 1.0 g/dL noninferiority margin.
MT1013Phase 3PeptideCaSR; OGPPartial signalNo reviewed efficacy summary in this indication
NNG-DEPO (Stimus)Phase 3Biologic (subtype unspecified)Erythropoietin receptor (EPO-R)Partial signalNo reviewed efficacy summary in this indication
Patiromer (Veltassa)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT01810939: Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031)
Pegmolesatide (HS-20039)Phase 3PeptideErythropoietin receptor (EPO-R)Reliable signal
NCT03903809: Mean Hb change from baseline: pegmolesatide +19.2 g/L vs epoetin alfa +15.4 g/L; between-group difference 3.8 g/L (95% CI 0.7-6.9), noninferiority margin -10 g/L
NCT03902691: Mean change in hemoglobin (baseline to evaluation period): +0.07 g/dL pegmolesatide vs -0.22 g/dL epoetin alfa; between-group difference 0.29 g/dL (95% CI 0.11-0.47), non-inferiority verified
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
Rilparencel (Neo-Kidney Augment / REACT)Phase 3Cell therapySelected renal cells (autologous, paracrine)Weak signal
NCT05018416: Primary endpoint (difference in annual eGFR slope, pre- vs post-treatment): Group 1 (n=24) -5.8 to -1.3 mL/min/1.73m2, difference 4.6 per year, 78% improvement, P < .001; Group 2 (n=25) -3.4 to -1.7 mL/min/1.73m2, difference 1.7 per year, 50% improvement, P = .085
Roxadustat (Evrenzo)Phase 3Small moleculeHIF prolyl hydroxylase (HIF-PH1/2/3)Reliable signal
NCT01750190: Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001).
NCT01887600: Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb Response (Baseline to week 24): Roxadustat 79.2% (95% CI 74.8 to 83.1) vs Placebo 9.9% (95% CI 6.1 to 14.8)
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SC0062Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
SHR6508Phase 3Small moleculeCalcium-sensing receptor (CaSR)Weak signalNo reviewed efficacy summary in this indication
Sodium Zirconium Cyclosilicate (Lokelma)Phase 3Small moleculeGastrointestinal potassium binderPartial signal
NCT05056727: Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) missed
Somatropin (Jintropin)Phase 3Biologic (subtype unspecified)Growth hormone receptorPartial signal
NCT03535415: HT-SDS change at week 52: +0.75 (rhGH-treated) vs +0.17 (untreated control), reported as statistically significant; enrollment (68) and design match NCT03535415 exactly, and the paper is indexed against this NCT.
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)Partial signal
NCT03242018: Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo (Baseline to Week 26): Sotagliflozin 400 mg -0.4 percentage of HbA1c (Standard Error 0.131) vs Placebo -0.11 percentage of HbA1c (Standard Error 0.151) missed
NCT03242252: Change From Baseline in HbA1c at Week 26 (Baseline to Week 26): Sotagliflozin 200 mg -0.32 percentage of HbA1c (Standard Error 0.06) | Sotagliflozin 400 mg -0.46 percentage of HbA1c (Standard Error 0.06) vs Placebo -0.22 percentage of HbA1c (Standard Error 0.061)
Upacicalcet (UPASITA)Phase 3Small moleculeCalcium-sensing receptor (CaSR)Partial signal
NCT05836220: PATH-2, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 43.5% versus 17.4%, for a difference in proportions of 26.1% (95% confidence interval, 17.4 to 34.8, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
NCT05832931: PATH-1, primary endpoint (iPTH reduction of at least 30%), upacicalcet vs placebo: 42.1% versus 16.8%, for a difference in proportions of 25.3% (95% confidence interval, 16.2 to 34.5, P < 0.001) (J Am Soc Nephrol, 2026-10-23).
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Partial signal
NCT06531824: Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). missed
NCT05182840: Change in log UACR at week 14 (all patients): 10 mg -0.553 vs placebo -0.066 (difference -0.486, 95% CI -0.660 to -0.313, p<0.0001); 20 mg -0.487 (difference -0.421, 95% CI -0.596 to -0.246, p<0.0001); 3 mg -0.235 (difference -0.168, 95% CI -0.337 to -0.000, p=0.0499). Adjusted median percent change: 10 mg -42.5% vs placebo -6.4%.
Zibotentan + DapagliflozinPhase 3Small moleculeEndothelin A receptor, SGLT2not yet gradedNo reviewed efficacy summary in this indication
ZigakibartPhase 3Monoclonal antibodyAPRIL (A Proliferation-Inducing Ligand, TNFSF13)not yet gradedNo reviewed efficacy summary in this indication
InaxaplinPhase 2/3Small moleculeAPOL1 (Apolipoprotein L1)Weak signal
NCT06794996: Single-group Phase 2b AMPLIFIED: UACR -42.7% (cohort 1) and -17.3% (AMKD with type 2 diabetes) from baseline at Week 13 (Vertex, 2026-09-22).
NCT04340362: The primary outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13 in participants with at least 80% adherence to inaxaplin therapy. Sixteen participants were enrolled; among the 13 who were treated and met the adherence threshold, the mean change from baseline at week 13 was -47.6% (95% confidence interval, -60.0 to -31.3).
KT-301Phase 2/3Microbiome therapeuticProbiotic live biotherapeuticnot yet gradedNo reviewed efficacy summary in this indication
AB002Phase 2Protein / enzyme therapeuticProtein CPartial signal
NCT03963895: Primary outcomes: 40 registered safety and tolerability counts (treatment-related adverse events, access-site bleeding, ECG, anti-thrombin antibodies, vital signs and laboratory changes); safety outcome, no formal efficacy test. Treatment-related TEAEs: 0 in each AB002 dose group and 0 with placebo (CT.gov posted results).
ALN-ANG3Phase 2RNA / oligonucleotideANGPTL3not yet gradedNo reviewed efficacy summary in this indication
Avacopan (Tavneos)Phase 2Small moleculeComplement C5a receptor 1 (C5aR1/CD88)Weak signalFeatured results are pharmacokinetic only in this race
CagrilintidePhase 2PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signalNo reviewed efficacy summary in this indication
UBT251Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
KP405
Phase 1(overall)
PeptideGLP-1/GIP receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 37 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

No upcoming readouts on record for this asset.